O. Wainberg

TL;DR: The addition of ramucirumab to front-line mFOLFOX6 did not improve PFS in the intent-to-treat (ITT) population, and an exploratory exposure-response analysis indicated that patients with higher ramucorumab exposure had longer OS.

Abstract: Gastric and gastroesophageal junction cancer (G/GEJC) is a heterogeneous and complex disease characterized by histologic and molecular subtypes. Although a growing number of treatments have improved survival outcomes in the advanced setting, the greatest therapeutic benefits are observed among patient populations eligible for biomarker-directed therapies. Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) is an emerging biomarker under phase 3 clinical investigation for G/GEJC with the novel monoclonal antibody bemarituzumab. FGFR2b protein overexpression in gastric cancer, together with its function in various oncogenic signaling pathways, makes it an attractive target for precision medicine and thereby has gained clinical interest for its potential prognostic role in G/GEJC. Thus, to explore the potential role of FGFR2b, this narrative review summarizes the role and mechanism of FGFR2b in advanced G/GEJC, describes appropriate detection methodology for FGFR2b protein overexpression, and discusses future considerations for precision treatment in advanced G/GEJC with respect to FGFR2b protein overexpression and the emergence of other biomarkers.

TL;DR: Neoadjuvant mFOLFIRINOX and Nivolumab was associated with favorable rates of R0 resection, PFS and OS relative to historical data in patients with BRPC in this pilot trial.

TL;DR: This phase II trial (MOUNTAINEER-02) evaluated tucatinib, trastuzumab, paclitaxel, and ramucirumab in HER2+ gastroesophageal cancer patients, showing a 76.5% overall response rate, 10.6-month median duration of response, and 11.9-month median progression-free survival.